|drug3401||Telephone interview Wiki||0.71|
|drug823||Cognitive Stimulation Wiki||0.71|
|drug3492||Tocilizumab Injection Wiki||0.50|
|D019965||Neurocognitive Disorders NIH||0.71|
|D060825||Cognitive Dysfunction NIH||0.41|
There are 2 clinical trials
In this study, defined cases of COVID-19 with mild, moderate or severe pneumonia will be treated with standard treatment regimens in combination with IV injection of Deferoxamine. Improvement in clinical, laboratory and radiological manifestations will be evaluated in treated patient compared to control group.
Description: All cause of deathMeasure: Mortality rate Time: up to 20 days
Description: Mild, Moderate or SevereMeasure: change in patients clinical manifestation Time: up to 20 days
Description: daysMeasure: Length of hospitalization Time: up to 20 days
Assessment of Efficacy and Safety of Tocilizumab Compared to DefeROxamine, associated with standards treatments in COVID-19 (+) patients, Hospitalized In Intensive care in Tunisia. Multicentric, comparative, randomized study.
Description: Evaluate the mortality rate at 90 days. Evaluate the Intensive Care Unit (ICU) and Hospital Mortality rate at day 90 with date and cause of death (if applicable)Measure: the mortality rate Time: 90 day
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports